中国癌症杂志2026，Vol.36Issue(7)：681-685,5.DOI:10.19401/j.cnki.1007-3639.2026.07.007
超声分子成像前沿:新型靶向超声造影剂BR55研究进展
Frontiers in ultrasound molecular imaging:research progress on the novel targeted ultrasound contrast agent BR55
王晓亭 1张波2
作者信息
- 1. 中日友好临床医学研究所,北京 100029
- 2. 国家呼吸医学中心,呼吸和共病全国重点实验室,国家呼吸疾病临床研究中心,中国医学科学院呼吸病学研究院,中日友好医院呼吸中心超声医学科,北京 100029
- 折叠
摘要
Abstract
BR55 is a lipid microbubble ultrasound molecular contrast agent targeting vascular endothelial growth factor receptor 2(VEGFR2).As a targeted ultrasound contrast agent that has entered clinical evaluation,BR55 marks the transition of ultrasound imaging from the anatomical and functional era into the molecular era.However,despite existing review articles discussing the preclinical research and preliminary clinical application of BR55,there is currently a lack of a detailed review focusing on the various stages of BR55 clinical trials,which limits the comprehensive planning and understanding of the clinical application path of BR55 technology.The latest advancements of this review are reflected in the systematic synthesis and summary of data from completed and ongoing clinical trials of BR55 across all phases,its imaging efficacy across various tumor types,and its potential as a therapeutic response biomarker.This review aims to provide cutting-edge references for domestic scholars and play a core role of ultrasound molecular imaging technology in precision medicine.关键词
BR55/血管内皮生长因子受体2/超声分子成像/靶向超声造影剂/临床试验Key words
BR55/Vascular endothelial growth factor receptor 2/Ultrasound molecular imaging/Targeted ultrasound contrast agent/Clinical trial分类
医药卫生引用本文复制引用
王晓亭,张波..超声分子成像前沿:新型靶向超声造影剂BR55研究进展[J].中国癌症杂志,2026,36(7):681-685,5.
